Propanc Biopharma, Inc.

A Leading Oncology Player

Developing Long-Term Therapy for the Treatment of Solid Tumors

Propanc Biopharma, Inc. is a clinical stage biopharmaceutical company focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. Together with our scientific and oncology consultants, we have developed a novel therapeutic approach based on 100 years of the scientific study of enzyme use. Our leading products not only treat metastatic cancer but reduce recurrence.

View Company PDF

Developing Long-Term Therapy for the Treatment of Solid Tumors

Latest Developments

Propanc Biopharma Initiates Development of Bio-Analytical Assay in Preparation for Human Trials

Learn More

Propanc Biopharma Commences Drug Discovery Research Collaboration

Learn More

Positioning ourselves for worldwide regulatory approval

Progressing development

The progressing development of a once-daily proteolytic proenzyme cancer treatment through non-clinical and clinical development, and ultimately, obtaining regulatory approval as an effective, clinically proven therapeutic option.

Multiple mechanisms of action

Unlike many products approved for the treatment of cancer, our treatment exerts multiple effects on cancerous cells, which inhibits tumor growth and potentially stops it from spreading throughout the body.

Encouraging data from patient treatment

Scientific research undertaken over the last 15 years and the clinical experience from treating patients in the UK and Australia has provided evidence that PRP may be an effective treatment against cancer, and warrants further development.

Unique intellectual property

We are focusing on building a significant portfolio of intellectual property around our scientific understanding of the effects of proteolytic proenzyme in cancer, identifying new formulations, new routes of administration and potential new therapeutic targets.

Increasing Demand for Easy-to-Administer Cancer Treatments

Cancer is the leading cause of death worldwide, accounting for 7.6 million deaths (around 13% of all deaths) in 2008.*

*Source: http://www.who.int/mediacentre/factsheets/fs297/en/
Supplying a Market Need

Technology Based on Pancreatic Enzyme Therapy

Pancreatic Enzyme Therapy uses natural elements within our organism that could help us treat cancer. We are developing a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis, the main cause of patient death from cancer.

How Our Technology Works
Play Video

A New Frontier In Cancer Therapy

Watch how Propanc is pioneering a new approach to cancer therapy

Halting Cancer Cells’ Ability to Invade and Metastasize

We are developing a therapeutic solution for the treatment of patients with advanced stages of cancer targeting solid tumors. Our therapy has anti-cancer effects that block tumor growth and its aggressive dissemination.

View Our Product Pipeline

The Propanc Difference

Instead of targeting tumor cell death, we focus on inducing cell differentiation. We convince malignant cells to stop proliferating and encourage them to continue their work as a specific cell type.

What Makes Us Different

An International R&D Network that’s Driven to Excellence

Our strong partnerships are helping to advance and perfect our technology and candidates.

The Andalusian Public Foundation for biomedical research in eastern Andalusia, Alejandro Otero-FIBAO is a non-profit foundation specializing in the comprehensive management of biomedical research.

We have a Joint IP Ownership and Commercialization Agreement with Bath University.

Our ongoing joint research collaboration with the University of Grenada and Universidad de Jaen involved investigating the effects of PRP on cancer cells, identifying molecular target identification and new compound screenings.

With the help of vivoPharm, we are conducting animal testing on PRP to determine its safety and efficacy, as well as determining metabolic effects prior to conducting human studies.

We have partnered with Q Biologicals to undertake the GMP-compliant investigational medicinal product (IMP) manufacture of PRP for human use.

Our ongoing joint research collaboration with The ibs.GRANADA involves studying the in-vivo effect of the anti-tumoral formulation of PRP against cancer stem cells.

Unique Intellectual Property

We are building an IP portfolio around our scientific understanding of the effects of proenzymes in cancer, identifying new formulations, new routes of administration and potential new therapeutic targets.

Ownership

  • A Joint Commercialization Agreement with Bath University
  • Bath University has assigned patents to us in exchange for rights for research use plus 2% royalties

Patent Details

  • A robust intellectual property portfolio with 65 patents either in force, or pending.

Prior Art

  • A U.S. patent, Trnka et al, Pharmaceutical composition containing an isolated protease proenzyme, amylase & aprotinin was filed in January, 1999
  • Novak & Trnka, Proenzyme Therapy of Cancer, Anti-cancer Research was filed in 2005

Current Status

  • We have four patent families covering several important discoveries regarding proenzymes and their anti-cancer effects.
  • We recently received additional composition claims as a continuation from the original foundation patent in the U.S.
  • A further two patent applications are in preparation covering composition of matter and method of use claims.

Backed by Strong Leadership

We use the strengths, capabilities and experience of our leadership team to help determine the future vision of the company, commercial objectives and operations.

View Management Team
View Board of Directors
View Scientific Advisors